These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 15087416)
1. Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-42. Schönthal AH Cancer Res; 2004 Apr; 64(8):2937; author reply 2938. PubMed ID: 15087416 [No Abstract] [Full Text] [Related]
2. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Swamy MV; Herzog CR; Rao CV Cancer Res; 2003 Sep; 63(17):5239-42. PubMed ID: 14500353 [TBL] [Abstract][Full Text] [Related]
3. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462 [TBL] [Abstract][Full Text] [Related]
4. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467 [TBL] [Abstract][Full Text] [Related]
6. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509 [TBL] [Abstract][Full Text] [Related]
8. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902 [TBL] [Abstract][Full Text] [Related]
9. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866 [TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Levitt RJ; Pollak M Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282 [TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Song X; Lin HP; Johnson AJ; Tseng PH; Yang YT; Kulp SK; Chen CS J Natl Cancer Inst; 2002 Apr; 94(8):585-91. PubMed ID: 11959891 [TBL] [Abstract][Full Text] [Related]
12. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Johnson AJ; song X; Hsu A; Chen C Adv Enzyme Regul; 2001; 41():221-35. PubMed ID: 11384747 [No Abstract] [Full Text] [Related]
13. [APHS and celecoxib, the new aspirins have arrived]. Bénard J Bull Cancer; 1998 Jul; 85(7):605. PubMed ID: 9752265 [No Abstract] [Full Text] [Related]
14. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821 [TBL] [Abstract][Full Text] [Related]
15. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. Wu GS; Zou SQ; Liu ZR; Tang ZH; Wang JH World J Gastroenterol; 2003 Jun; 9(6):1302-6. PubMed ID: 12800245 [TBL] [Abstract][Full Text] [Related]
17. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Kawamori T; Rao CV; Seibert K; Reddy BS Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081 [TBL] [Abstract][Full Text] [Related]
18. [Therapy with preferential and specific COX-2 inhibitors]. Stichtenoth DO; Frölich JC Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028 [No Abstract] [Full Text] [Related]
19. A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery. Reuben SS Spine (Phila Pa 1976); 2001 Jul; 26(13):1505-6. PubMed ID: 11458162 [No Abstract] [Full Text] [Related]
20. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]